OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry
Xinyu Li, Rudolf T. Hoogenveen, Mohamed El Alili, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 10, pp. 1249-1262
Open Access | Times Cited: 8
Xinyu Li, Rudolf T. Hoogenveen, Mohamed El Alili, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 10, pp. 1249-1262
Open Access | Times Cited: 8
Showing 8 citing articles:
Investigating socioeconomic disparities in prescribing new diabetes medications in individuals with type 2 diabetes and very high cardiovascular risk in the Netherlands
Frank H. Ardesch, Rose J. Geurten, Jeroen N. Struijs, et al.
Primary care diabetes (2025)
Open Access
Frank H. Ardesch, Rose J. Geurten, Jeroen N. Struijs, et al.
Primary care diabetes (2025)
Open Access
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Versus Uptitrated Metformin in Patients with Type 2 Diabetes without Adequate Glycemic Control: A Randomized Clinical Trial
Lixin Guo, L. S. Wang, D. Tian, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 11, pp. 2351-2366
Open Access | Times Cited: 3
Lixin Guo, L. S. Wang, D. Tian, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 11, pp. 2351-2366
Open Access | Times Cited: 3
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling
Isaac Corro Ramos, Talitha Feenstra, Salah Ghabri, et al.
PharmacoEconomics (2024) Vol. 42, Iss. 7, pp. 715-719
Open Access | Times Cited: 2
Isaac Corro Ramos, Talitha Feenstra, Salah Ghabri, et al.
PharmacoEconomics (2024) Vol. 42, Iss. 7, pp. 715-719
Open Access | Times Cited: 2
KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD
Amy K. Mottl, Susanne B. Nicholas
American Journal of Kidney Diseases (2023) Vol. 83, Iss. 3, pp. 277-287
Closed Access | Times Cited: 6
Amy K. Mottl, Susanne B. Nicholas
American Journal of Kidney Diseases (2023) Vol. 83, Iss. 3, pp. 277-287
Closed Access | Times Cited: 6
Comment on “SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect”
Rose Peronard, Stephan Peronard Mayntz
American Journal of Cardiovascular Drugs (2024)
Closed Access | Times Cited: 1
Rose Peronard, Stephan Peronard Mayntz
American Journal of Cardiovascular Drugs (2024)
Closed Access | Times Cited: 1
Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection
Thijs Jansz, Katherine Young, Rhian Hopkins, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Thijs Jansz, Katherine Young, Rhian Hopkins, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus—Clinical Practice Position Statement of the Polish Society of Nephrology
Marcin Adamczak, Ilona Kurnatowska, Beata Naumnik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12941-12941
Open Access
Marcin Adamczak, Ilona Kurnatowska, Beata Naumnik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12941-12941
Open Access
